Sabbin Sakamako Mai Kyau don Maganin Arthritis Psoriatic

Sakin Kyauta | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

ACELYRIN, INC., Affibody AB, da Inmagene Biopharmaceuticals Co., Ltd., a yau sun sanar da cewa 16-mako, duniya, Phase 2 gwajin asibiti na izokibep a cikin marasa lafiya 135 tare da cututtukan cututtuka na psoriatic (PsA) sun hadu da farkon ƙarshen ACR50. Izokibep kuma ya sami maki na biyu na ƙarshe, gami da amsawar PASI, haɓaka haɓakar LEEDs na enthesitis, da ingantacciyar rayuwa akan ingantaccen ingancin kayan rayuwa na PsA na asibiti, tambayoyin Tambayoyin Tasirin Cutar Psoriatic (PsAID).   

Bazuwar makafi biyu, mai sarrafa wuribo, gwaji na asibiti na Phase 2 ya kimanta aminci da ingancin izokibep dosed 80 MG kowane mako biyu (Q2W) ko 40 mg Q2W, tare da placebo Q2W, a cikin manya marasa lafiya tare da PsA mai aiki. Babban ƙarshen ƙarshen ACR50 da ƙarshen ƙarshen PASI an sadu da su kuma sun kasance a saman kewayon martani, idan aka kwatanta da abin da aka ruwaito don wasu magungunan da aka yarda ko ci gaba don PsA. Adadin marasa lafiya tare da ƙuduri na enthesitis ya bayyana yana bambanta. An sami ci gaba mai ma'ana na asibiti a cikin takamaiman yanayin rayuwa tare da ma'aunin sakamakon da aka ba da rahoton haƙuri, PsAID. Ba a gano sabbin al'amurran tsaro ba.

“Kyakkyawan bayanan da aka samar a cikin wannan gwaji na Mataki na 2 suna goyan bayan hasashen mu cewa ƙarfin ƙarfi da ƙananan ƙwayoyin izokibep yana haifar da yuwuwar bayyanar da girma kuma, don haka, mafi inganci. Ingantacciyar shigar da miyagun ƙwayoyi a cikin ƙanƙara, ƙananan ƙwayoyin entheseal marasa kyau za su kasance daidai da bambance-bambancen ragi mai zafi da aka gani tare da jiyya na izokibep, "in ji Paul Peloso, MD, babban jami'in kula da lafiya (CMO) na ACELYRIN.

“Ragowar ciwon entheseal yana da alaƙa da mafi munin cuta da ƙarancin ingancin rayuwa. Abin farin ciki ne ganin irin wannan ingantaccen ƙuduri na enthesitis da ingantacciyar rayuwar marasa lafiya, ”in ji shi.

“Psoriatic Arthritis cuta ce mai raɗaɗi kuma mai raɗaɗi na kumburin haɗin gwiwa, fata, da kusoshi, kuma yana iya shafar kashin baya. Mun ji daɗin wannan gwaji na Mataki na 2 yana nuna yuwuwar izokibep don ba da ingantaccen tasiri na asibiti a cikin wannan yanki na ci gaba da buƙata,” in ji Farfesa Nikolai Brun, MD, PhD, CMO na Affibody. "Mahimmanci, dama ta rage don ci gaba da bincika mafi girman abubuwan da za a iya ɗauka don inganta amsa kuma har yanzu isar da izokibep azaman allurar SC guda ɗaya."

Shao-Lee Lin, MD, PhD, wanda ya kafa kuma Shugaba na ACELYRIN, ya ce, "Wadannan bayanan suna nuna amincewarmu ga dabarun da aka sanar a baya na cikakken kimanta yuwuwar hana IL-17A don ingantaccen canji a cikin jihohin cututtuka da yawa."

"Bayanan PsA P2 suna da tasiri mai kyau musamman ga axial spondyloarthritis (AxSpA) da psoriasis (PsO), wanda aka ba da tasiri akan enthesitis da amsa PASI. Za a yi nazari mafi girma (160mg QW) da Q2W dosing na izokibep a cikin wani muhimmin nazari na PsA P2b/3 a matsayin mataki na gaba na ci gaban shirin," in ji ta.

David Bejker, Shugaba na Affibody, ya ce, "Wadannan sakamakon binciken suna da mahimmanci wajen nuna damar da za a samar da mafi kyawun abubuwan da ke cikin aji bisa fasahar Affibody®."

Za a raba cikakkun bayanai na bayanan gwaji na PsA Phase 2 ta hanyar gabatarwa a taron Ƙungiyar Ƙungiyoyin Ƙungiyoyin Rheumatology ta Turai (EULAR) a Copenhagen a ranar 3 ga Yuni, 2022, da karfe 11:05AM CET.

ACELYRIN tana riƙe haƙƙoƙin duniya na izokibep ban da haɓakawa da haƙƙin kasuwanci na Inmagene a zaɓaɓɓun ƙasashen Asiya, gami da China, Hong Kong, Koriya ta Kudu, da Taiwan, ban da Japan. Affibody yana riƙe da haƙƙin kasuwanci a cikin ƙasashen Nordic.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...